All In Biotech

Drug Trial Radar · NCT03330847

To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.

A Phase II, Open Label, Randomised, Multi-centre Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination With Olaparib Versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR)-Related Genes (Including BRCA1/2) (VIOLETTE).

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 273 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

273

Actual

Start

Mar 7, 2018

Primary completion

Nov 13, 2020

Study completion Oct 9, 2026

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Nov 6, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to assess the efficacy and safety of olaparib monotherapy versus olaparib in combination with an inhibitor of ATR (Ataxia-Telangiectasia Mutated (ATM) and Rad3-related protein kinase (Ceralasertib \[AZD6738\]) and olaparib monotherapy versus olaparib in combination with an inhibitor of WEE1 (adavosertib \[AZD1775\]) in second or third line setting in patients with Triple-negative breast cancer (TNBC) prospectively stratified by presence/absence of qualifying tumour mutation in genes involved in the homologous recombination repair (HRR) pathway. Treatment arms are olaparib monotherapy, olaparib+ Ceralasertib and olaparib+adavosertib. The study subject population will be divided into Stratum A, Stratum B, and Stratum C. Due to the different schedules of administration of each of the treatment options as well as their different toxicity profiles, the study is not blinded. Study has two stage consent process- stage 1 consent (molecular screening for HRR defects) and stage 2 consent (main study). Patients with TNBC and with known qualifying BRCAm, non BRCAm HRRm and non HRRm status will be offered the option of consenting to the main part of the study within the 28-day screening period. Following the ISRC meeting on 17 April 2019 a recommendation was made to close the adavosertib+olaparib treatment arm across all biomarker strata. Patients receiving treatment with adavosertib+olaparib treatment were offered the opportunity to continue treatment on olaparib monotherapy at the approved dose (300 mg bd). Following the closure of this arm the total number of patients randomised will be lower (approximately 350 patients). Approximately 300 patients will be randomised (using randomisation ratio 1:1) to 2 ongoing treatment arms plus an additional 47 patients to a 3rd arm (olaparib+adavosertib) prior to the arm being discontinued.

Conditions

  • Metastatic Triple Negative Breast Cancer

Interventions

  • Olaparib Continuous (28-Day cycle) 300 mg BD.Drug

    Two (2) 150 mg olaparib tablets should be taken at the same time each day, approximately 12 hours apart with one glass of water (approximately 250 mL).

  • Ceralasertib 160 mg OD + olaparib continuous 300 mg BD (28-day cycle).Drug

    Patients will be administered Ceralasertib OD at 160 mg from Day 1 to Day 7 (inclusive) of every 28-day cycle.

  • Adavosertib 150 mg BD + olaparib 200 mg BD (21-day cycle).Drug

    Patients will be administered adavosertib BD at 150mg from Day 1 to Day 3 and Day 8 to Day 10.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival Per Stratum (BICR)Time frame: Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)
  2. Progression-free Survival Per Stratum (Sensitivity Analysis)Time frame: Until date of first documented progression or censoring date or date of death from any cause, whichever came first (assessed up to 32 months)

Locations

141 sites in 15 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Anchorage, Alaska

  • Research Site

    Gilbert, Arizona

  • Research Site

    Aurora, Colorado

  • Research Site

    New Haven, Connecticut

  • Research Site

    Chicago, Illinois

  • Research Site

    Munster, Indiana

  • Research Site

    Hazard, Kentucky

  • Research Site

    Louisville, Kentucky

  • Research Site

    Towson, Maryland

  • Research Site

    Brick, New Jersey

  • Research Site

    East Setauket, New York

  • Research Site

    Lake Success, New York

  • Research Site

    Mineola, New York

  • Research Site

    Mount Kisco, New York

  • Research Site

    Stony Brook, New York

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Knoxville, Tennessee

  • Research Site

    Seattle, Washington

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Brasschaat, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Brussels, Belgium

  • Research Site

    Charleroi, Belgium

  • Research Site

    Leuven, Belgium

  • Research Site

    Liège, Belgium

  • Research Site

    Namur, Belgium

  • Research Site

    Ottignies, Belgium

  • Research Site

    Wilrijk, Belgium

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Kelowna, British Columbia, Canada

  • Research Site

    Ottawa, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Brno, Czechia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Angers, France

  • Research Site

    Besançon, France

  • Research Site

    Bordeaux, France

  • Research Site

    Caen, France

Showing 40 of 141 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.